News dal mondo
09
Mar
US FDA drafts guidance on best practices for responding to inspection observations
The US Food and Drug Administration (FDA) has released a draft guidance detailing how manufacturers should address Form 483 observations following a drug good manufacturing practice (GMP) inspection. This guidance applies to both domestic and international inspections. FDA is accepting comments on the draft guidance on www.regulations.gov under docket number FDA-2025-D-1504 through 6 May...[FDA]
The US Food and Drug Administration (FDA) has released a draft guidance detailing how manufacturers should address Form 483 observations following a drug good manufacturing practice (GMP) inspection. This guidance applies to both domestic and international inspections.
FDA is accepting comments on the draft guidance on www.regulations.gov under docket number FDA-2025-D-1504 through 6 May...[FDA]
28
Apr
Sun Pharma compra Organon
Sun Pharmaceutical Industries ha firmato un accordo definitivo per acquisire Organon &...
27
US QMM: Participants scored well on commitment to quality, lower on advanced manufacturing
Pharmaceutical companies participating in the US Food and Drug Administration (FDA) Quality Maturity...
23
Top Drugs at Risk of Supply Shortages
Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively...
Regulatory considerations for pharmaceutical excipient selection
The article discusses the role and importance of excipients in medicines, focusing on regulatory aspects...
le ultime news
24 Mar
Farmaceutica italiana: export boom verso gli Usa, ma cresce la dipendenza dalla Cina
20 Mar
Iran, blocco Hormuz su produzione farmaci: 'se dura ci sarà impatto tra 6 mesi'
19 Mar
Nuove norme UE sui farmaci: più incentivi all’innovazione e controllo della disponibilità
As Iran war squeezes Middle East drug shipments, experts warn of longer-term effects on US manufacturing, generics
Farmalabor: investiti 8,5 milioni in un progetto per le malattie rare
17 Mar
EMA Management Board: highlights of March 2026 meeting
13 Mar
Dal China all’India-shoring, il rischio di una nuova dipendenza
11 Mar
EU Finalizes Pharma Reform Package, Clarifies New Rules On Modular Market Protection
<<<3 4 5>>>
